Preparation and characterization of novel coenzyme Q10 nanoparticles engineered from microemulsion precursors

AAPS PharmSciTech

Volumn 4, Issue 3, 2003, Pages

  Hsu, Cheng Hsuam ^a   Cui, Zhengrong ^a   Mumper, Russell J ^a   Jay, Michael ^a  

^a University of Kentucky   (United States)

Author keywords

Cell uptake; Coenzyme Q10; Microemulsion; Nanoparticles; Stability

Indexed keywords

NANOPARTICLE; POLYOXYETHYLENE STEARYL ETHER; POLYSORBATE 20; UBIDECARENONE;

ANIMAL CELL; AQUEOUS SOLUTION; ARTICLE; CONTROLLED STUDY; COOLING; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG SOLUTION; DRUG STABILITY; DRUG STORAGE; DRUG SYNTHESIS; DRUG UPTAKE; FREEZE DRYING; IN VITRO STUDY; LOW TEMPERATURE; MACROPHAGE; MICROEMULSION; MOUSE; NONHUMAN; PARTICLE SIZE; PHARMACEUTICAL ENGINEERING; SLOW DRUG RELEASE; STORAGE TEMPERATURE; TEMPERATURE MEASUREMENT;

EID: 23144437239     PISSN: 15309932     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/pt040332     Document Type: Article

References (32)

1. Frei B, Kim MC, Ames BN. Ubiquinol-10 is an effective lipid-soluble antioxidant at physiological concentrations. Proc Natl Acad Sci U S A. 1990;87:4879-4883.
2. 10 (ubiquinone). Clin Investig. a 1993;71(suppl 8): S116-S123.
3. Casey AC, Bliznakov EG. Effect and structure-activity relationship of coenzymes Q on the phagocytic rate of rats. Chem Biol Interact. 1972;16:1504-1510.
4. 10 nanoparticles. Pharm Res. 1995;12:201-208.
5. 10: a new drug for a cardiovascular disease. J Clin Pharmacol. 1990;30:590-608.
6. 10 preparations in Japan. In: Folkers K, Yamamura Y, eds. Biomedical and Clinical Aspects of Coenzyme Q. Vol 4. Amsterdam: Elsevier Science; 1984:131-142.
7. 10 formulations in healthy volunteers. Mol Aspects Med. 1994;15(suppl):S273-S280.
8. Takeuchi H, Sasaki H, Niwa T, Hino T, Kawashima Y, Uesugi K, Ozawa H. Improvement of photostability of ubidecarenone in the formulation of a novel powdered dosage form termed redispersible dry emulsion. Int J Pharm. 1992;86:25-33.
9. 10 with cyclodextrins. Acta Pol Pharm. 1995;52:379-386.
10. 10: formulation development and bioavailability assessment. Int J Pharm. 2001; 212:233-246.
11. Maincent P, LeVerge R, Sado P, Couvreur P, Devissaguet JP. Disposition kinetics of vicamine loaded polyalkylcyanoacrylate nanoparticles. J Pharm Sci. 1986;75:955-958.
12. El-Shabouri MH. Positively charged nanoparticles for improving the oral bioavailability of cyclosporin-A. Int J Pharm. 2002;249:101-108.
13. Mathiowitz E, Jacob JS, Jong YS, Carino GP, Chickering DE, Chaturvedi P, Santos CA, Vijayaraghavan K, Montgomery S, Bassett M, Morrell C. Biologically erodible microspheres as potential oral drug delivery systems. Nature. 1997;386:410-414.
14. Bunjes H, Drechsler M, Koch MH, Westesen K. Incorporation of the model drug ubidecarenone into solid lipid nanoparticels. Pharm Res. 2001;18:278-293.
15. Desai MP, Labhasetwar V, Amidon GL, Levy RJ. Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm Res. 1996;13:1838-1845.
16. 10 and triiodothyronine. J Control a Release. 2001;75:237-247.
17. 10-loaded PMMA nanoparticles by a new emulsification process based on microfluidization. Colloids and Surfaces A. 2002;210:95-104.
18. Cui Z, Mumper RJ. Genetic immunization using nanoparticles engineering from microemulsion precursors. Pharm Res. 2002;19:939-946.
19. Cui Z, Mumper RJ. Plasmid DNA-entrapped nanoparticles engineered from microemulsion precursors: in vitro and in vivo evaluation. Bioconjug Chem. 2002;13:1319-1327.
20. Cui Z, Mumper RJ. Intranasal administration of plasmid DNA-coated nanoparticles results in enhanced immune responses. J Pharm Pharmacol. 2002;54:1195-1203.
21. Cui Z, Hsu C-H, Mumper RJ. Physical characterization and macrophage cell uptake of mannan-coated nanoparticles. Drug Dev Ind Pharm. 2003;29:689-700.
22. 10) delivery: preparation and characterization [abstract]. AAPS PharmSci. 2002;4(4):W5120.
23. 10 in vesicles composed of archaeal ether lipids or conventional lipids enhances the immuno-adjuvanticity to encapsulated protein. Vaccine. 1998;16:1504-1510.
24. 10) aqueous simple using reversed phase liquid chromatography. Pharmazie. 2001;56:394-396.
25. Schwarz C, Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery II. Drug incorporation and physical characterization. J Microencapsul. 1999;16:205-213.
26. Martin A, Swarbrick J, Cammarata A. Physical Pharmacy: Physical Chemical Principles in the Pharmaceutical Sciences. 3rd ed. Philadelphia, PA: Lea & Febiger; 1983:452-454.
27. Schwarz C, Mehnert W. Freeze-drying of drug-free and drug-loaded solid lipid nanoparticles (SLN). Int J Pharm. 1997;157:171-179.
28. Chen DB, Yang TZ, Lu WL, Zhang Q. In vitro and in vivo study of two types of long-circulating solid lipid nanoparticles containing paclitaxel. Chem Pharm Bull. 2001;49:1444-1447.
29. Doebbler GF. Cryoprotective compounds. Cryobiology. 1966;3:2-11.
30. Ford AW, Dawson PJ. The effect of carbohydrate additives in the freeze-drying of alkaline phosphatase. J Pharm Pharmacol. 1993;45:86-93.
31. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur J Pharm Biopharm. 2000;50:161-177.
32. Saiki I, Tokushima Y, Nishimura K, Azuma I. Macrophage activation with ubiquinones and their related compounds in mice. Int J Vitam Nutr Res. 1983;53:312-320.